A detailed history of China Universal Asset Management Co., Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,742 shares of SAGE stock, worth $63,876. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,742
Previous 7,070 66.08%
Holding current value
$63,876
Previous $76,000 10.53%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.02 - $13.08 $32,797 - $61,109
4,672 Added 66.08%
11,742 $84,000
Q2 2024

Jul 19, 2024

SELL
$10.58 - $17.9 $47,440 - $80,263
-4,484 Reduced 38.81%
7,070 $76,000
Q1 2024

Apr 29, 2024

BUY
$18.62 - $26.95 $85,968 - $124,428
4,617 Added 66.56%
11,554 $217,000
Q4 2023

May 21, 2024

SELL
$17.1 - $22.26 $78,950 - $102,774
-4,617 Reduced 39.96%
6,937 $150,000
Q4 2023

Jan 23, 2024

BUY
$17.1 - $22.26 $92,442 - $120,337
5,406 Added 353.1%
6,937 $150,000
Q3 2023

May 21, 2024

BUY
$16.75 - $48.98 $12,529 - $36,637
748 Added 95.53%
1,531 $31,000
Q3 2023

Oct 30, 2023

BUY
$16.75 - $48.98 $12,529 - $36,637
748 Added 95.53%
1,531 $32,000
Q2 2023

May 21, 2024

SELL
$40.65 - $59.54 $1,056 - $1,548
-26 Reduced 3.21%
783 $36,000
Q2 2023

Jul 27, 2023

SELL
$40.65 - $59.54 $1,056 - $1,548
-26 Reduced 3.21%
783 $37,000
Q1 2023

May 21, 2024

BUY
$37.27 - $46.57 $7,603 - $9,500
204 Added 33.72%
809 $33,000
Q1 2023

Apr 27, 2023

BUY
$37.27 - $46.57 $7,603 - $9,500
204 Added 33.72%
809 $34,000
Q4 2022

May 21, 2024

SELL
$32.2 - $43.61 $352,557 - $477,485
-10,949 Reduced 94.76%
605 $23,000
Q4 2022

Jan 31, 2023

BUY
$32.2 - $43.61 $1,577 - $2,136
49 Added 8.81%
605 $23,000
Q3 2022

Oct 21, 2022

BUY
$32.28 - $43.27 $17,947 - $24,058
556 New
556 $22,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.